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Abstract
Background: Inflammatory response following initial improvement with anti-tuberculosis (TB) treatment has been
termed a paradoxical reaction (PR). HIV co-infection is a recognised risk, yet little is known about other predictors of
PR, although some biochemical markers have appeared predictive. We report our findings in an ethnically diverse
population of HIV-infected and uninfected adults.
Methods: Prospective and retrospective clinical and laboratory data were collected on TB patients seen between
January 1999–December 2008 at four UK centres selected to represent a wide ethnic and socio-economic mix of TB
patients. Data on ethnicity and HIV status were obtained for all individuals. The associations between other potential
risk factors and PR were assessed in a nested case-control study. All PR cases were matched two-to-one to controls by
calendar time and centre.
Results: Of 1817 TB patients, 82 (4.5 %, 95 % CI 3.6–5.5 %) were identified as having a PR event. The frequency of PR
was 14.4 % (18/125; 95 % CI 8.2–20.6 %) and 3.8 % (64/1692; 2.9–4.7) for HIV-positive and HIV-negative individuals
respectively. There were no differences observed in PR frequency according to ethnicity, although the site was more
likely to be pulmonary in those of black and white ethnicity, and lymph node disease in those of Asian ethnicity.
In multivariate analysis of the case-control cohort, HIV-positive patients had five times the odds of developing PR
(aOR = 5.05; 95 % CI 1.28–19.85, p = 0.028), whilst other immunosuppression e.g. diabetes, significantly reduced the
odds of PR (aOR = 0.01; 0.00–0.27, p = 0.002). Patients with positive TB culture had higher odds of developing PR
(aOR = 6.87; 1.31–36.04, p = 0.045) compared to those with a negative culture or those in whom no material was sent
for culture. Peripheral lymph node disease increased the odds of a PR over 60-fold 4(9.60–431.25, p < 0.001).
Conclusion: HIV was strongly associated with PR. The increased potential for PR in people with culture positive TB
suggests that host mycobacterial burden might be relevant. The increased risk with TB lymphadenitis may in part arise
from the visibility of clinical signs at this site. Non-HIV immunosuppression may have a protective effect. This study
highlights the difficulties in predicting PR using routinely available demographic details, clinical symptoms or
biochemical markers.
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Background
Inflammatory response associated with treatment for tu-
berculosis (TB) has been termed a paradoxical reaction.
This is defined as a worsening of clinical or radiological
findings following the initiation of appropriate anti-
tuberculosis treatment, in the absence of evidence of dis-
ease relapse or the presence of another diagnosis [1].
HIV co-infection is a well-recognised risk factor for this,
usually when concomitant anti-retroviral therapy (ART)
is started [2] and is termed the Immune Reconstitution
Inflammatory Syndrome (IRIS). This is thought to occur
when a functioning immune response returns by the
action of ART and worsens TB symptoms during
treatment [3], or where undiagnosed TB is ‘unmasked’
by ART [4]. TB itself is immunomodulatory, and ini-
tiation of TB treatment can also reverse immunedys-
regulation [5].
In non-HIV positive people, the reported frequency of
PR varies widely, but is lower than that seen in HIV
positive people [1, 3]. Further, there is some evidence
that the immune response differs by ethnic group [6].
Some have considered that PR may occur as a result of
pre-existing allergies to medication [7]. Despite advances
in our understanding of the immunological profile of pa-
tients who develop IRIS, such as recognition of the role
of tumour necrosis factor α (TNF- α) and interleukin-6
[8] and other CD4 T-cell activation inflammatory cyto-
kines and chemokines [9], and apart from introduction
of ART in HIV-positive individuals, little is known
regarding simple to measure baseline predictive factors
for PR during anti-tuberculosis therapy [10]. There have
been several, small case series from East Asia that have
identified risk factors for developing PR. One Taiwanese
study of 16 PR cases showed that decreased serum
haemoglobin, albumin level, and lymphocyte count were
associated with increased risk of pulmonary TB PR com-
pared to over 600 patients who did not develop PR,
although in multivariate analysis the differences just
reached statistical significance at 5 % [11]. Another study
of 16 individuals from Hong Kong found that lower
lymphocyte counts at baseline and extrapulmonary dis-
ease were identified risk factors compared to 53 patients
who did not develop PR [12]. For pleural TB, younger
age, high serum albumin level, low proportion of
lymphocytes and high proportion of polymorphonuclear
cells in pleural fluid was found in 32 patients in South
Korea [13]. In another Korean study, 72 patients with
pleural TB developed PR, with increased eosinophil
count and protein levels in baseline pleural fluid identi-
fied as risk factors [14]. Earlier analysis from our group
suggested that culture-positive TB predicted PR [15].
To investigate further associations, we conducted a
multi-site UK study to determine the relationship be-
tween baseline presenting factors, ethnicity and reported
PR frequency. Unlike previous studies, here we present
patients with a wide range of ethnicities, and explore the
impact of the site of active TB disease on PR, and the ef-
fect of HIV and the use of ART compared to other pos-
sible causes of PR.
Methods
Study design
Cohort study and nested case control study.
Setting
Four UK centres who were a collaborative group of TB
partners with a wide mix of ethnicities across their pa-
tient populations. Anonymised demographic and clinical
data were collated from the Homerton (HH), Royal Free
(RFH), and Guy’s and St Thomas’ Hospitals (STH) in
London, and Royal Blackburn Hospital (RBH), Blackburn.
Participants
The cohort comprised all patients with a diagnosis of
TB (culture-positive, or culture-negative with a response
to TB treatment and no other possible diagnosis) recorded
between January 2002 and December 2008 for RFH and
HH, January 1999 and December 2008 (Blackburn) and
mid-2006 and 2008 (STH, for all patients with electronic
notes available). All data were retrospectively collated ex-
cept for RFH, where half was prospectively collected as
part of a study into PR. Baseline data for HIV status and
collated ethnicities were recorded for all subjects based on
United Kingdom Government’s Office for National Statis-
tics definitions [16]. For example, this grouping includes
Black-British, Black-African and Black-Caribbean. PR was
diagnosed using the clinical definition detailed above and
defined by Breen et al [1]. Possible PR cases were then
confirmed by the site specific leads and the principal au-
thor on review of patient notes. Two site leads maintained
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a prospective register of all consecutive TB cases (HH
and RBH), including those who has been identified as
having a PR event. Two sites reviewed all case notes for
evidence of PR (RFH and STH). Patients were followed
up for the duration of treatment and reviewed accord-
ing to local policy, normally one clinic visit after treat-
ment cessation.
Those who defaulted follow-up or were found to
have another diagnosis were not included in the final
assessment. Sequential registration of patients was
two to one matched to cases to assess risk factors
for PR development, with those who definitely did
not have any worsening of symptoms matched to
those with a recorded PR. If there were any doubt
regarding allocation or uncertainty of symptoms for
controls then the subsequent registration was used
to ensure that only definitive cases and controls
were included in analysis. Figure 1 displays the par-
ticipant groups.
Variables
Recorded information included basic demographic de-
tails; medical, drug, and allergy history; symptoms at TB
diagnosis; physical examination; pre-treatment biochem-
ical, haematological and inflammatory markers; radio-
graphic and histological tests; TB diagnostic tests; and
symptoms and evidence of PR.
Statistical methods
The overall incidence of PR at the four participating
centres was calculated, with corresponding 95 %
confidence interval (CI). The incidence of PR according
to HIV status and ethnic group was also calculated, and
compared using a chi-squared test. Finally, the site of
disease was summarised according to ethnicity to gain a
descriptive understanding of any potential differences.
In the nested case-control study, potential factors
associated with PR were examined. Parameters were
chosen in advance of analysis: these were demo-
graphic factors (age, sex, and ethnicity); immunosup-
pression (HIV, non-HIV immunosuppression, and the
potential immune-modulatory lifestyle factors tobacco
and alcohol use); baseline TB disease site, symptoms &
microbiology; and baseline blood parameters (total white
cell count, lymphocyte count, haemoglobin; albumin and
alkaline phosphatase; C-reactive protein and erythrocyte
sedimentation rate; lactose dehydrogenase and vitamin D
levels).
Analyses were performed using conditional logistic
regression to account for matching by calendar time
and centre. In order to arrive at a parsimonious
model, those potential factors with p ≤ 0.1 in univari-
ate analyses were included in the multivariate model,
along with a priori assumptions that were brought
forward for inclusion (age and sex as routine, and
HIV status and TB culture result from our previous
findings). No formal adjustments for multiple compar-
isons were made. Missing data were accounted for
with categorical variables, although missing baseline
blood tests were not imputed, and analysis limited to
those with a blood test available. STROBE guidelines
were adhered to for reporting [17].
Fig. 1 Study population
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Results
Total patient group
Of 1817 patients treated for TB for whom records were
reviewed, 82 (4.5 %, 95 % CI 3.6–5.5 %) subjects with PR
were identified. Fifty-five percent of PR cases were
female, with a median age of 32 years (IQR 26–41).
Twenty-two percent of people with PRs were HIV co-
infected (compared to an overall prevalence of 6.9 % of
the total 1817 patients). The frequency of PR in the HIV
positive group was 14.4 % (95 % CI 8.2–20.6 %) com-
pared to 3.8 % (95 % CI 2.9–4.7) in the HIV negative or
untested group (p < 0.001).
Table 1 shows the proportion of PR within different
racial groups, disaggregated by HIV status. There was no
difference in frequency of PR among the different eth-
nicities in either the HIV positive or HIV negative or
unknown groups (p = 0.73 and p = 0.15). Information on
the proportion of patients tested for HIV was available
for HH (where testing was performed in 100 % of cases),
RFH (testing in 95 %) and STH (92 % cases). At RBH,
this was not routinely performed however all patients
from injecting drug users or sub-Saharan Africa were
tested.
Amongst the 82 individuals who experienced PR, the
site of disease varied by ethnic group (Table 2). Extra-
pulmonary lymph node involvement was found to be
significantly more common among South Asians than
Blacks adjusted for other ethnicities (p = <0.001). Those
of Black ethnicity conversely exhibited more pulmonary
involvement than people of South Asian and White eth-
nicity (p = 0.045). There was a higher prevalence of sys-
temic symptoms such as fever and sweating amongst
those of black and white, compared to South and East
Asian ethnicity (40 and 50 % versus 2 and 17 % respect-
ively; p = 0.004). HIV co-infection was more common in
these PR populations (47 % in the Black PR population
and 38 % in the White, none in other groups), though
HIV status was not measured in 18 (22 %) of cases. Of
note, within the HIV negative population, there was
no greater prevalence of baseline systemic symptoms
across ethnicities compared to the HIV positive population
(p = 0.485). Where timing of ART initiation was re-
corded in HIV positive patients, ART was started
prior to or at the time of PR development in 10 cases
(56 %) and following TB treatment in 5 cases (28 %).
3 HIV positive patients were not recorded as receiv-
ing ART (17 %).
The majority of PR occurred at the presenting site of
TB disease (81; 88 %), with 91 % (84) having an exacer-
bation of pre-diagnosis symptoms. The median time of
onset of PR was at week 4.5 (IQR 3–11, maximum of
150 weeks in one patient who represented after treat-
ment completion). The median duration of PR was
4 weeks (range 1–46 weeks). Forty-five percent (41) re-
ceived treatment with steroids.
Case control analysis
In total 152 controls were selected for the 82 cases; 12
cases could only be matched to one control, and 70
cases were matched to two controls. Table 3 provides in-
formation on selected demographics, baseline inflamma-
tory markers, allergies reported to medication, TB smear
and culture, and presenting symptoms in the PR and
non-PR groups. There were no observed differences in
age or sex between cases or controls. Pulmonary disease
was more common as the presenting site of initial dis-
ease in controls (63 % versus 38 %), and peripheral
lymph nodes more frequent in PRs (42 % versus 3 %;
p < 0.001). There were somewhat more HIV-positive
individuals in the PR group (22 % versus 16 %; p = 0.41).
A positive mycobacterial culture and Nucleic Acid
Amplification Technique (NAAT), lack of tobacco and
alcohol use, a raised baseline ESR, the absence of non-
HIV immunosuppression (defined here as diabetes melli-
tus, cancer, chronic renal failure or pregnancy), and
presence of initial site of disease at extrathoracic lymph
nodes were associated with development of PR in uni-
variate analysis. In multivariate analysis (Table 4), pres-
ence of baseline LN disease, TB culture positivity, HIV
positive status, and presence of non-HIV immunosup-
pression were all associated with the development of PR
at a 5 % level of significance.
Table 1 Ethnicity, HIV status and PR
Ethnicity Total
number
Number HIV
positive (%)
Paradoxical reaction number (%; 95 % confidence intervals)
Total population HIV positive HIV negative/unknown
Black 555 96 (17.3) 32 (5.8; 3.7–7.5) 15 (15.6;8.4–22.9) 17 (3.7; 2.0–5.4)
East Asian 98 5 (5.1) 6 (5.1; 1.4–10.9) – 6 (6.5; 1.5–11.4)
Mixed Race 11 – 0 – –
Other 50 4 (13.3) 3 (6.3; 0–12.6) – 3 (6.5; 0.0–13.7)
South Asian 786 2 (2.5) 33 (5.7; 2.8–5.6) – 33 (4.2; 2.6–5.6)
White 317 18 (5.7) 8 (5.1; 0.8–4.3) 3 (16.7; 0–33.9) 5 (1.7; 0.2–3.1)
Total 1817 125 (6.9) 82 (4.5; 3.6–5.6) 18 (14.4; 8.2–20.6) 64 (3.8; 2.9–4.7)
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The association with HIV was confirmed in multivari-
ate analysis, where the odds ratio of developing PR were
5.05 (95 % CI 1.28–19.85, p = 0.028) compared to those
without known HIV infection.
Lymph node disease was associated with a 64.33-fold
increased odds of having a PR event (95 % CI 9.60–
431.25, p < 0.001). A positive TB culture increased the
odds of developing PR 6.87 times (95 % CI 1.31–36.04,
p = 0.045). Though NAAT showed an association, the
greatest percentage difference in the non-PR and PR
groups was in those who did not have a test per-
formed. Finally, non-HIV immunosuppression reduced
the risk of PR significantly (aOR 0.01; 95 % CI 0.00–0.27,
p = 0.002).
Baseline ESR could not be fitted within the multivari-
ate model due to the limited numbers of people in
whom this was measured (n = 48 in cases, n = 91 in con-
trols, only 97 of which were able to be used in matched
case control analysis; see Table 3). Sensitivity analysis
dividing ESR into either three or four categories con-
firmed increasing odds of PR with increasing ESR, but
again this could not be fitted into multivariate analysis
due to small numbers. ESR is often moderately elevated
in HIV infection [18]. In univariate analysis a 1-log in-
crease in ESR was associated with a 4.43 increased odds
of developing PR (95 % CI 1.30–15.1); this association
remained in sensitivity analysis when adjusted for HIV
status (aOR 4.78; 1.29–17.72, p = 0.019).
Discussion
Within our total population, we find that HIV is strongly
associated with development of PR, mainly in the con-
text of ART initiation within the case control cohort
(55 % started ART before or at time of PR development).
The observed frequency of 14.4 % within the HIV
positive group is similar to that of 15.7 % reported in
a meta-analysis of 3500 HIV co-infected patients [19].
In the HIV negative or unknown group our observed
frequency of 3.8 % is also in line with published
observations (ranging from 2 % in all patients to
25 % in extra-pulmonary tuberculosis) [1, 2, 20]. The
long length of time to PR onset that can occur (up to
a maximum of 150 weeks in our cohort) has been
previously recognised [21], and our observed median
time to onset is similar to other general studies [1],
though shorter than those looking solely at extra-
pulmonary PR [20].
We observed an association between the location of
the PR site and ethnicity, although the overall rate of PR
did not differ between ethnic groups. This likely arises
because baseline disease site (which does appear to have
a racial origin) heavily influences the site of PR: our
Black and White study populations had more pulmonary
disease compared to those of South Asian ethnicity, in
whom lymphadenitis predominates. This is in keeping
with other reports [22].
Our findings suggest that peripheral lymph node dis-
ease greatly predisposes to PR; despite large confidence
intervals, the increased risk is pronounced, in the magni-
tude of sixty-fold increased odds in multivariate analysis.
This has been previously documented as a likely site of
IRIS. In the third British Thoracic Society lymph node
study, carried out in a predominantly South Asian cohort
between 1987–89 i.e. largely without HIV co-infection,
new lymphadenopathy was reported in 16 % in the first
three months of treatment [23], and new nodes or sinuses
in 7–12 % after treatment completion [24]. We cannot ex-
clude ascertainment bias as a possible cause of this; and
PR at other less easily-identifiable locations might be
under-reported in the absence of systemic symptoms justi-
fying further investigations. This potential confounding
supports the need for an international consensus to en-
sure that all potential paradoxical reactions are appropri-
ately identified and recorded to improve epidemiology
and surveillance [25].
As reported with TB meningitis IRIS in South Africa
[26] and disseminated TB in a Malaysian HIV cohort
[27], the increased potential for PR in people with
Table 2 Site of PR by ethnicity
Site of PRa Number of patients by ethnicity (percentage of total ethnic group with PR)
Black East Asian Other South Asian White
Total 32 (100 %) 6 (100 %) 3 (100 %) 33 (100 %) 8 (100 %)
Chestb 15 (47 %) 1 (17 %) – 6 (18 %) 1 (13 %)
Systemic Symptomsc 13 (40 %) 1 (17 %) – 2 (6 %) 4 (50 %)
Abdominal 6 (19 %) – – – 1 (13 %)
Brain 2 (6 %) – – – –
Peripheral lymph nodes 8 (25 %) 4 (67 %) 3 (100 %) 25 (76 %) 4 (50 %)
Other 2 (6 %) 1 (17 %) 1 (33 %) 1 (3 %) 3 (38 %)
aPR may occur at more than one site for each patient, so percentages do not sum to 100 %
bPulmonary, pleural, and mediastinal lymph nodes
cSystemic symptoms are persistent fever and persistent night sweats
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Table 3 Univariate analysis of baseline variables at TB diagnosis in case control cohort
Variable (N = 234 total unless otherwise stated) PR (%) (N = 82) Matched control without PR (N = 152) P value*
Demographicsa
Age (Mean) 33.7 37.0 0.162
Sex (%) Male 72 (45 %) 72 (47 %) –
Female 45 (55 %) 80 (53 %) 0.770
Ethnicity (%) White 8 (10 %) 26 (17 %) –
Black 32 (39 %) 65 (43 %) –
East Asian 6 (7 %) 9 (6 %) –
South Asian 33 (40 %) 46 (30 %) –
Other 3 (4 %) 6 (4 %) 0.663
Baseline TB disease site, symptoms & microbiology
Site (%) Chest b 29 (35 %) 96 (63 %) –
Abdominal 2 (2 %) 4 (3 %) –
Brain 2 (2 %) 5 (3 %) –
Peripheral lymph nodes 34 (41 %) 4 (3 %) –
Other or mixed sites 15 (18 %) 43 (28 %) <0.001
Systemic Symptoms (%)c (with weight loss) Yes 23 (28 %) 45 (30 %) –
No 54 (66 %) 101 (66 %) –
Not recorded 5 (6 %) 6 (4 %) 0.901
Systemic Symptoms (%)c (without weight loss) Yes 27 (33 %) 64 (42 %) –
No 50 (61 %) 82 (54 %) –
Not recorded 5 (6 %) 6 (4 %) 0.332
Acid Fast Bacilli (%) Negative 47 (57 %) 88 (58 %) –
Positive 25 (30 %) 42 (28 %) –
Not performed 10 (12 %) 22 (14 %) 0.770
M. tuberculosis NAAT (%) Negative 8 (10 %) 9 (6 %) –
Positive 20 (24 %) 24 (16 %) –
Not performed 54 (66 %) 119 (78 %) 0.007
M. tuberculosis Culture (%) Negative 13 (16 %) 37 (24 %) –
Positive 62 (76 %) 104 (68 %) –
Not performed 7 (9 %) 11 (7 %) 0.256
Immune system functioning
HIV status (%) Negative 46 (56 %) 101 (66 %) –
Positive 18 (22 %) 25 (16 %) –
Not recorded 18 (22 %) 26 (17 %) 0.413
Drug allergies (%) No 34 (41 %) 60 (39 %) –
Yes 2 (2 %) 2 (1 %) –
Not recorded 46 (56 %) 90 (59 %) 0.688
Immunosuppression (%)d No 80 (98 %) 130 (8^%) –
Yes 1 (1 %) 17 (11 %) –
Not recorded 1 (1 %) 5 (3 %) 0.004
Potential immune–modulating lifestyle factors
Tobacco use (%) No 60 (73 %) 97 (64 %) –
Yes 10 (12 %) 37 (24 %) –
Not recorded 12 (15 %) 18 (12 %) 0.101
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culture positive tuberculosis confirms that underlying
host mycobacterial burden appears important in the
development of PR, though some culture negative dis-
ease may not in fact be TB but rather another diag-
nosis. Therefore culture positive disease could be
over-represented artefactually in analysis. It should be
noted, however, that we also found PRs in apparent
low mycobacterial burden disease (as 16 % were cul-
ture negative at baseline).
There was evidence that the combined group of
non-HIV immunosuppression including diabetes was
associated with reduced odds of developing PR. Whilst
the numbers in this heterogeneous population are small
(n = 18, seven of whom were diabetic, and none were
using or recently withdrawn from biologic treatments)
with wide confidence intervals, PR has occurred in oncol-
ogy patients receiving granulocyte colony-stimulating fac-
tor post chemotherapy, though not when functionally
impaired [28], and on TNF-α antagonist withdrawal [29].
We are unaware of a reported association between PR and
diabetes, and this subgroup should be explored in larger
datasets.
Although numbers were small, we observed a trend
towards a lower risk of developing PR with increased
alcohol use (aOR 0.21; 0.04–1.01; group categorical p value
of 0.009, alcohol use versus no alcohol, p = 0.051). This,
again, would be interesting to further evaluate in a larger
study.
Recent studies have suggested that baseline C-Reactive
Protein (CRP) is associated with the risk of developing
PR in HIV co-infected individuals [30, 31]. This requires
confirmation in a larger longitudinal study. From our
data it appears that the Erythrocyte Sedimentation rate
(ESR), which has also been shown to be raised at base-
line in TB [32] may be a useful predictive marker or PR.
Given the limited data on ESR within our cohort, this
will require further work to determine whether an asso-
ciation exists.
Strengths and limitations
There are several limitations of this study. Ascertain-
ment of development of PR was collected retrospectively
at two centres, and therefore we cannot be certain all
true PR cases were identified, although case notes were
reviewed thoroughly by both the site PI and the study
lead author. Furthermore, the case control nature of the
primary analysis limits the potential biases caused by
this. Selection bias may result in identification of the
more severe cases that required treatment. In particular
for some blood measures, not all tests were performed
in all patients. For the total population, HIV testing was
not performed in every patient and although testing was
routinely offered at the diagnosis of TB, there is the poten-
tial for HIV status to be assessed more assiduously in diag-
nosed or suspected PR cases. The one setting where this
was not performed regularly has a low overall HIV preva-
lence. In our study, where known, overall testing rates for
HIV were above 90 %. Given the relatively small numbers
of PR, some confidence intervals are wide in multivariate
analysis. However the large baseline denominator from
whom the controls were drawn had a broad representa-
tion of age, ethnicity, sex, and baseline disease. We believe
our findings highlight areas for future study, and can be
generalised to other population settings.
Table 3 Univariate analysis of baseline variables at TB diagnosis in case control cohort (Continued)
Alcohol use (%) No 59 (72 %) 85 (56 %) –
Yes 8 (10 %) 34 (22 %) –
Not recorded 15 (18 %) 33 (22 %) 0.007
Geometric mean (range) baseline blood test resultse (units, number of patients with variable data)
White blood cell count (cells/μL, n = 229) 7.2 (3.1–16.1) 7.2 (2.1–18.4) 0.953
Lymphocyte Count (cells/μL, n = 229) 1.6 (0.4–4.2) 1.6 (0.3–6.5) 0.855
Haemoglobin (g/dL, n = 230) 11.7 (7.7–16.0) 12.0 (7.1–17.3) 0.285
Albumin (g/dL, n = 225) 38 (16–77) 37 (9–50) 0.501
Alkaline Phosphatase (U/L, n = 225) 134 (44–823) 123 (14–1074) 0.627
C-Reactive Protein (mg/L, n = 203) 62 (1–280) 65 (1–396) 0.939
Erythrocyte Sedimentation Rate (mm/h, n = 139) 56 (6–132) 46 (2–129) 0.017
Vitamin D Levels (ng/mL, n = 85) 27.1 (8.6–79.4) 30.9 (6.3–168.0) 0.764
Lactate Dehydrogenase (U/L, n = 99) 499 (294–1156) 523 (246–2127) 0.699
* P values calculated using Wald tests in conditional logistic regression
aDemographic information available for all patients
bPulmonary, pleural, and mediastinal lymph nodes
cSystemic symptoms are persistent fever and persistent night sweats
dNon-HIV immunosuppressive state such as diabetes mellitus, cancer, chronic renal failure or pregnancy
eLog means were used for analysis to approximate normal distributions for skewed tails
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Conclusions
Overall, this retrospective case control study highlights
the known association between HIV and PR during TB
treatment. It did not succeed in identifying any clear
additional positive or negative risk factors apart from
possible mycobacterial burden and non-HIV immuno-
suppression; or confirm previous blood parameters from
smaller studies. This demonstrates the difficulties in pre-
dicting PR using routinely available demographic details,
clinical symptoms or biochemical markers. It also high-
lights the apparent frequency of PR when it occurs at
visibly apparent sites such as peripheral lymph nodes.
To determine whether PR risk stratification, based on
easy to measure variables at initial presentation is pos-
sible, greater numbers of prospectively-gathered PR
cases need to be assessed. A positive result would enable
people at highest risk to be monitored carefully, with ap-
propriate therapy started to treat, or even prevent PR.
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